CIPROXIN

This brand name is authorized in Austria, Cyprus, Finland, Hong Kong SAR China, Ireland, Italy, Malta, Netherlands, New Zealand, UK.

Active ingredients

The drug CIPROXIN contains one active pharmaceutical ingredient (API):

1	Ciprofloxacin hydrochloride monohydrate UNII 4BA73M5E37 - CIPROFLOXACIN HYDROCHLORIDE
	Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.
	Read more about Ciprofloxacin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
Ciproxin Tablets 250mg	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01MA02	Ciprofloxacin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01M Quinolone antibacterials → J01MA Fluoroquinolones
Discover more medicines within J01MA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FI	Lääkealan turvallisuus- ja kehittämiskeskus	195065
GB	Medicines & Healthcare Products Regulatory Agency	138499, 147117, 161495, 302678, 34926, 380958, 381253, 381394
HK	Department of Health Drug Office	29934, 29936
IE	Health Products Regulatory Authority	18341, 18953, 18961, 57738
IT	Agenzia del Farmaco	026664019, 026664021, 026664096, 043270014, 044542013, 044941019, 045631013, 045858014
MT	Medicines Authority	MA639/01702, PI908/02903A
NL	Z-Index G-Standaard	14177676, 14177684
NL	Z-Index G-Standaard, PRK	50083, 50091
NZ	Medicines and Medical Devices Safety Authority	5027